Major postpartum hemorrhage (PPH) continues to account for a substantial proportion of maternal deaths worldwide. Despite routine uterotonic use during the third stage of labor, refractory atonic PPH remains a significant clinical challenge. When initial medical measures fail, intrauterine tamponade is widely recommended as a second-line intervention to control uterine bleeding.
Two mechanical tamponade strategies with differing mechanisms are in current use. Uterine balloon tamponade (UBT) controls hemorrhage by applying direct intrauterine pressure against bleeding surfaces. The vacuum-assisted hemorrhage-control device (VHD), by contrast, uses negative pressure with the stated aim of promoting uterine contraction and thereby reducing bleeding. Comparative clinical data on these modalities are limited, motivating direct comparisons in protocolized care pathways.
The work summarized in the available abstract is a retrospective cohort study undertaken at the National University Hospital in Singapore. The study period reported covers January 2020 through September 2025. Patients included were women treated for primary PPH who received either UBT or VHD as part of a protocol-driven care pathway during that interval.
The article is listed in Acta Obstetricia et Gynecologica Scandinavica (online ahead of print) and bears PMID 42559737 and DOI 10.1111/aogs.70334. The multi-author team includes clinicians from obstetrics, gynecology, anesthesia, and biostatistics units at the National University Health System and collaborating institutions.
The abstract contrasts the two devices' mechanisms of action:
Uterine balloon tamponade (UBT): achieves hemostasis primarily via application of positive intrauterine pressure, compressing bleeding vessels and facilitating clot formation.
Vacuum-assisted hemorrhage-control device (VHD): is designed to apply negative pressure within the uterine cavity, with the intention of stimulating uterine contraction as a mechanism to reduce bleeding.
The study aimed to compare the clinical effectiveness of these two approaches when used for refractory atonic PPH within a standardized care pathway.
The abstract indicates a comparison of clinical effectiveness but the provided excerpt does not list the study's predefined primary or secondary endpoints, nor does it describe specific outcome measures. Typical endpoints for tamponade device studies include measures such as attainment of hemostasis without additional surgical intervention, total blood loss, need for blood transfusion, subsequent laparotomy or hysterectomy, ICU admission, and maternal morbidity; however, the source excerpt did not specify which of these were used or how they were operationalized in this study.
The available abstract text in the source is truncated and stops during the methods section ("during which ROT..."). Consequently, no numeric results, event counts, comparative statistics, effect estimates, or authors' conclusions were available for extraction from the provided source content. Any attempt to summarize study findings numerically or qualitatively beyond what is stated in the incomplete abstract would risk introducing information not present in the source.
The primary limitation for this summary is that the supplied PubMed/NCBI abstract is incomplete. Key missing elements include:
Because these details were not present in the provided source, they are explicitly not reported here.
From the available text, the study's rationale—to compare UBT and VHD for refractory atonic PPH within a protocolized setting—is clear and clinically relevant given limited comparative evidence. However, without the full methods and results, no evidence-based recommendations can be drawn from this abstract alone. Clinicians should consult the full published article to review the study population, outcomes, effect sizes, statistical analyses, and any stated limitations before considering changes to practice.
This retrospective cohort study from a tertiary center in Singapore sought to compare the clinical effectiveness of uterine balloon tamponade and a vacuum-assisted hemorrhage-control device for refractory atonic PPH within a protocol-driven pathway. The provided PubMed abstract is truncated and does not report essential methodological details or results. For complete findings and guidance on clinical applicability, readers should retrieve and read the full article (Acta Obstet Gynecol Scand; DOI 10.1111/aogs.70334, PMID 42559737).